| Literature DB >> 26473076 |
Ilker Ilhanli1, Necip Guder2, Murat Gul3.
Abstract
BACKGROUND: Despite the insufficient evidence, due to potential contribution to the improvement, platelet-rich plasma (PRP) is emerging as a promising method.Entities:
Keywords: Platelet-Rich Plasma; Shoulder; Tear
Year: 2015 PMID: 26473076 PMCID: PMC4601247 DOI: 10.5812/ircmj.23732
Source DB: PubMed Journal: Iran Red Crescent Med J ISSN: 2074-1804 Impact factor: 0.611
Comparison of Females and Males for Demographic Data
| Variables | Female (n = 45) | Male (n = 17) | P Value |
|---|---|---|---|
|
| 57.62 ± 10.89 | 64.23 ± 6.29 | 0.005 [ |
|
| 28.37 ± 4.80 | 27.08 ± 3.33 | 0.313 |
|
| 6.86 ± 3.67 | 8.23 ± 4.10 | 0.210 |
a Significance level: P < 0.05.
Comparison of Platelet-Rich Plasma and Physical Treatment Groups for Range of Motion, Visual Analog Scale, Disabilities of Arm, and Shoulder and Hand and Beck Depression Inventory Scores [a,b]
| Evaluation Steps (a, b, c) | PRP, n = 30 | PT, n = 32 | P Value |
|---|---|---|---|
|
| |||
| a | 94.77 ± 40.83 | 111.09 ± 31.81 | 0.083 |
| b | 109.70 ± 36.86 | 132.03 ± 29.04 | 0.010 [ |
| c | 129.33 ± 30.47 | 157.65 ± 31.57 | 0.001 [ |
|
| |||
| a | 25.53 ± 9.07 | 19.37 ± 9.73 | 0.013 [ |
| b | 27.86 ± 7.65 | 27.81 ± 9.49 | 0.980 |
| c | 28.70 ± 7.79 | 33.75 ± 9.91 | 0.030 [ |
|
| |||
| a | 84.66 ± 38.41 | 103.28 ± 27.28 | 0.031 [ |
| b | 94.33 ± 36.76 | 125.93 ± 29.60 | 0.000 [ |
| c | 109.83 ± 30.32 | 147.81 ± 33.93 | 0.000 [ |
|
| |||
| a | 24.16 ± 6.83 | 22.75 ± 7.13 | 0.429 |
| b | 28.50 ± 5.43 | 28.40 ± 7.72 | 0.956 |
| c | 34.00 ± 7.24 | 35.21 ± 7.64 | 0.522 |
|
| |||
| a | 33.83 ± 16.95 | 31.40 ± 18.28 | 0.590 |
| b | 37.66 ± 15.68 | 44.06 ± 18.07 | 0.143 |
| c | 42.83 ± 16.85 | 60.15 ± 20.18 | 0.001 [ |
|
| |||
| a | 65.66 ± 14.54 | 44.53 ± 19.27 | 0.000 [ |
| b | 76.50 ± 11.60 | 59.84 ± 18.55 | 0.000 [ |
| c | 84.16 ± 8.91 | 72.34 ± 19.00 | 0.003 [ |
|
| |||
| a | 7.80 ± 1.78 | 6.96 ± 1.95 | 0.087 |
| b | 5.43 ± 2.01 | 4.37 ± 1.93 | 0.039 [ |
| c | 2.70 ± 1.48 | 2.59 ± 1.73 | 0.798 |
|
| |||
| a | 2.86 ± 2.01 | 3.53 ± 2.07 | 0.206 |
| b | 1.56 ± 1.35 | 1.87 ± 1.47 | 0.396 |
| c | 0.30 ± 0.65 | 0.84 ± 1.32 | 0.045 [ |
|
| |||
| a | 7.03 ± 2.07 | 4.12 ± 3.07 | 0.000 [ |
| b | 4.33 ± 2.39 | 2.00 ± 2.32 | 0.000 [ |
| c | 1.60 ± 1.92 | 1.00 ± 1.90 | 0.222 |
|
| |||
| a | 66.26 ± 10.89 | 58.88 ± 14.07 | 0.025 [ |
| b | 51.35 ± 11.02 | 46.64 ± 14.03 | 0.150 |
| c | 35.62 ± 9.68 | 36.46 ± 14.58 | 0.790 |
|
| |||
| a | 69.66 ± 19.02 | 56.25 ± 17.55 | 0.005 [ |
| b | 53.33 ± 14.22 | 41.56 ± 13.22 | 0.001 [ |
| c | 48.83 ± 77.40 | 30.78 ± 13.20 | 0.199 |
|
| |||
| a | 22.64 ± 17.38 | 19.93 ± 15.58 | 0.520 |
| b | 20.78 ± 16.28 | 18.69 ± 14.41 | 0.593 |
| c | 17.87 ± 13.10 | 16.26 ± 12.67 | 0.625 |
a Abbreviations: a, before the treatment; b, after the treatment, c, the 12th month after the treatment; BECK, Beck depression inventory score; DASH, disabilities of arm, shoulder and hand; DASH work, DASH work model score; PRP, platelet-rich plasma; PT, physical therapy; ROM, range of motion (flexion, extension, abduction, adduction, external rotation, and internal rotation in degrees); VAS, visual analog scale.
b Date are presented as mean ± SD.
c Significance level: P < 0.05.
Comparison of the Differences of Means Between the Evaluation Steps for Platelet-Rich Plasma and Physical Treatment Groups [a]
| Evaluation Steps (a, b, c) | PRP Group (n = 30), Difference of Means | PT Group (n = 32), Difference of Means |
|---|---|---|
|
| ||
| a-b | 14.93 | 20.94 [ |
| b-c | 19.63 [ | 25.62 [ |
| a-c | 34.56 [ | 46.56 [ |
|
| ||
| a-b | 2.33 | 8.43 [ |
| b-c | 0.83 | 5.93 [ |
| a-c | 3.16 | 14.37 [ |
|
| ||
| a-b | 9.66 | 22.66 [ |
| b-c | 15.50 | 21.87 [ |
| a-c | 25.16 [ | 44.53 [ |
|
| ||
| a-b | 4.33 [ | 5.66 [ |
| b-c | 5.50 [ | 6.81 [ |
| a-c | 9.83 [ | 12.47 [ |
|
| ||
| a-b | 3.83 | 12.66 [ |
| b-c | 5.16 | 16.09 [ |
| a-c | 9.00 [ | 28.75 [ |
|
| ||
| a-b | 10.33 [ | 15.31 [ |
| b-c | 7.66 [ | 12.50 [ |
| a-c | 18.50 [ | 27.81 [ |
|
| ||
| a-b | 2.36 [ | 2.59 [ |
| b-c | 2.73 [ | 1.78 [ |
| a-c | 5.10 [ | 4.37 [ |
|
| ||
| a-b | 1.30 [ | 1.66 [ |
| b-c | 1.27 [ | 1.03 [ |
| a-c | 2.57 [ | 2.69 [ |
|
| ||
| a-b | 2.70 [ | 2.13 [ |
| b-c | 2.73 [ | 1.00 |
| a-c | 5.43 [ | 3.13 [ |
|
| ||
| a-b | 14.91 [ | 12.24 [ |
| b-c | 15.73 [ | 10.17 [ |
| a-c | 30.64 [ | 22.41 [ |
|
| ||
| a-b | 16.33 | 14.69 [ |
| b-c | 4.50 | 10.78 [ |
| a-c | 20.83 [ | 25.47 [ |
|
| ||
| a-b | 1.85 | 1.24 |
| b-c | 2.91 | 2.43 |
| a-c | 4.76 | 3.67 |
a Abbreviations: a, Before the treatment; b, After the treatment; c, the 12th month after the treatment; a-b, difference of means before the treatment and at the end of the treatment; b-c, difference of means at the end of the treatment and at the 12th month after the treatment; a-c, difference of means before the treatment and at the 12th month after the treatment; BECK, Beck depression inventory score; DASH, disabilities of arm, shoulder and hand; DASH work, DASH work model score; PRP, platelet-rich plasma; PT, physical therapy; VAS, visual analog scale.
b Significance level: P < 0.05.